Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia

Iron(iii)-binding of the anticancer agents doxorubicin and vosaroxin

(2015) Katja Dralle Mjos et al.   DALTON TRANSACTIONS

Azacitidine for the treatment of relapsed and refractory AML in older patients

(2015) Raphael Itzykson et al.   LEUKEMIA RESEARCH

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

(2015)   Oncotarget

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

(2014) Robert K. Stuart et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

(2014) J. E. Lancet et al.   HAEMATOLOGICA

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

(2014) Gail J. Roboz et al.   JOURNAL OF CLINICAL ONCOLOGY

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

(2013) A. K. Burnett et al.   BLOOD

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

(2013) Ciara Freeman et al.   EXPERT OPINION ON PHARMACOTHERAPY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

(2011) J E Lancet et al.   LEUKEMIA

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

(2010) Caroline D. Scatena et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

(2010) E. J. Walsby et al.   HAEMATOLOGICA

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II

(2010) Rachael E. Hawtin et al.   PLoS One

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models

(2008) Ute Hoch et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Metabolism of (+)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acid (Voreloxin; Formerly SNS-595), a Novel Replication-Dependent DNA-Damaging Agent

(2008) M. J. Evanchik et al.   DRUG METABOLISM AND DISPOSITION